Michael Robern - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Michael Robern

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Canadian Family Physician Medecin De Famille Canadien|October 13, 2023

Syphilis: The great imitatorRosalind Ashton, Michael Robern

Journal of Cutaneous Medicine and Surgery|June 21, 2012

Biologic therapy in psoriasis: perspectives on associated risks and patient managementKim A Papp, Joel Dekoven, Laurie Parsons, et al.

Rheumatology (Oxford, England)|September 9, 2021

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled studyVictoria P Werth, Roy Fleischmann, Michael Robern, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Canadian Family Physician Medecin De Famille Canadien|October 13, 2023

Syphilis: The great imitatorRosalind Ashton, Michael Robern

Journal of Cutaneous Medicine and Surgery|June 21, 2012

Biologic therapy in psoriasis: perspectives on associated risks and patient managementKim A Papp, Joel Dekoven, Laurie Parsons, et al.

Rheumatology (Oxford, England)|September 9, 2021

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled studyVictoria P Werth, Roy Fleischmann, Michael Robern, et al.

Pageof 1